Needle Free Injection Market is estimated to reach a high CAGR 15% during the forecast period 2023-2030. Needle-free injection (NFI) is a relatively newer technology that delivers drugs or vaccines either intramuscularly or subcutaneously using a narrow, precise fluid stream. Several benefits of the needle-free injection system include self-administration of medications and elimination of needle phobia. Needle-free injection systems encompass a wide range of drug delivery systems. Highly viscous drug administration is possible which cannot be administered by traditional syringe systems.
The global needle-free injection market growth is driven by the rising demand for vaccinations and biosimilars, instant drug delivery technology, increasing rate for self-injection devices, and growing chronic diseases.
The increasing incidence of communicable disease due to needle stick injuries
The introduction of universal precautions and safety-conscious needle designs has led to a decrease in needlestick injuries but still does occur. The Centers for Disease Control and Prevention (CDC) has developed a model that helps healthcare professionals recognize when to start antiretroviral therapy.
Nurses were the most affected staff resulted commonly from disposing of syringes. In contrast, the incidence of NSIs among physicians was where surgical devices were the primary source of NSIs has greater among them. Thus the growing incidence of communicable disease due to needle stick injuries is driving the growth of the market in the forecast period.
Increasing demand for self-injection devices is driving the growth
Self-Injection devices allow patients with chronic diseases to gain control of their treatment schedule and their treatment setting, thus allowing greater independence and freedom in their social, domestic, and professional lives. Self-injection may also offer psychological benefits over administration by healthcare professionals, including improved self-esteem. Removing the need to attend a clinic or hospital for regular injections also brings economic benefits to both the patient and the healthcare system. This economic benefit of self-injection devices has been the major growth driving factor for needle-free injection market. Increasing prevalence of chronic autoimmune diseases like rheumatoid arthritis and cancer have also helped the growth as self-injections have application in recovery from these illnesses. These factors are driving the growth of the market in the forecast period.
High development cost of needle-free injection system over conventional needle injection is likely to hamper the market growth
However, the needle-free injection can be manufactured in a variety of ways, however, the widely employed procedure to manufacture it is by an injection molding technique. There are many variants of this technology that are being marketed, such as Bioject ZetaJetTM, Vitajet 3, Tev-Tropin, and so on. Larger investment has been made in developing this technology. Thus the high cost of developing a needle-free injection system over the conventional needle injection will hamper the market growth in the forecast period.
According to the fierce pharma study, needle phobia may account for 10% of COVID-19 vaccine hesitancy, there is potential for alternative delivery routes to clear a barrier to vaccination. Scancell has advanced its effort to provide an alternative by tapping PharmaJet for needle-free delivery technologies. Regulators in South Africa cleared Scancell to run a phase 1 clinical trial of the vaccine candidates in July. The investigators will administer the vaccines using the PharmaJet Tropis and PharmaJet Stratis needle-free injection systems. After showing its vaccines are safe, Scancell plans to test the effects of giving a dose to people in the U.K. who have previously received two shots of an existing COVID-19 jab. The study will provide a pointer to the potential for the vaccine to play a role in booster campaigns. The growing needle phobia among people has driven the needle-free injection market in the forecast period.
A liquid-based segment is expected to grow at the fastest CAGR during the forecast period (2023-2030)
Liquid NFI has a larger share in the market. The entire mechanism of achieving a successful injection with a needle-free injection depends upon the ability of a liquid jet, stronger enough to penetrate the skin and the underlying fat layer without harming the skin or the integrity of the drug molecule.
Liquid NFI employs a high-speed jet to puncture the skin and deliver drugs without the use of a needle. They have been used to deliver a number of macromolecules including vaccines and insulin, as well as small molecules, such as anesthetics and antibiotics.
Powder-based has the second-largest share in the market. Powder needle-free injection depends on being able to formulate the particles of sufficient density and accelerating them to sufficient velocity strong enough to penetrate the skin and in a quantity sufficient enough to reach the therapeutic dose levels. This was made successful by using helium as a power source assisted by modifications in the ways of formulation of the drug as the conversion of the drug either pure or along with excipients into hard particles of 10-50 nm in diameter, with a density approximately the same as a crystalline drug. Coating the drug onto gold spheres which may act as a vector of a few micrometers in diameter, this method is mostly applicable to DNA vaccines.
The drug is stored in a “cassette” designed so as to house the drug in the center, while the cassette is capped with a polymeric lid, upon activation a gust of helium gas ruptures the lid, forcing the drug forward due to specially designed convergent-divergent type nozzles the drug particles attain the speed near about to that of sound, hence penetrating the skin.
Drug delivery through this system is limited only to those candidates with an effective dose of about 1 mg max. Since in powder drug delivery through NFIT systems, it is difficult to predict the proportion of dose that is difficult to determine the proportion of dose that is to be delivered to the epidermis, also the maximum payload for a 20 mm diameter target area of skin is about 2-3 mg. This technology is highly suitable for DNA vaccines and the delivery of local anesthetic to the skin and oral mucosa.
North America region holds the largest market share of global needle free injection market
North America dominated the needle free injection market is 2020 due to rising demand for biologics, technological advancements, mergers and acquisitions by major companies in the market, favorable reimbursement policies, increasing healthcare expenditure and regulatory approvals of new injection system are key factors driving the market growth in the region.
Needlestick injuries are known to occur frequently in healthcare settings and can be serious. In North America, millions of healthcare workers use needles in their daily work, and hence, the risk of needlestick injuries is always a concern. Today the major concern after a needle stick injury is not HIV but hepatitis B or hepatitis C. Guidelines have been established to help healthcare institutions manage needle stick injuries and when to initiate post-exposure HIV prophylaxis. The Centers for Disease Control and Prevention (CDC) has developed a model which helps healthcare professionals know when to start antiretroviral therapy.
Healthcare professionals at the highest risk for needle stick injuries are surgeons, emergency room workers, laboratory room professionals, and nurses. The use of needles is unavoidable in healthcare, and even though every hospital has guidelines on proper handling and disposal of needles and the newest design of safety-conscious needles, needle stick injuries continue to occur more often in et al. healthcare professionals like surgeons and emergency room personnel. In most cases, needle stick injuries occur chiefly because of unsafe practices and gross negligence on the part of the healthcare workers. Thus the growing cases of needlestick injuries in the region are driving the growth of the market in the forecast period.
The needle-free injection market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Endo International, PharmaJet, Fierce Pharma, Medical International Technology, INJEX Pharma, National Medical Products, European Pharma Group, PenJet Corporation, and Crossject among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the anal fistula globally. For instance, in October 6, 2020, Pharma Jet, Straits Needle-free Injection System will be used to deliver a vaccine against SARS-CoV-2 in a clinical trial in Australia. The DNA-based vaccine COVIGEN was developed by French-Thai pharmaceutical company BioNet and Melbourne-based biotech Technovalia.
Overview: PharmaJet, Inc., is a medical device company. The Company manufactures needle-free drug and vaccine delivery systems. The company's devices use a narrow stream of fluid that flows intra-muscularly through the skin without a needle, thereby enabling physicians to eliminate needlestick injuries, needle reuse, cross-contamination, and sharps waste disposal.
Permacol Surgical Implant: Permacol surgical implant is a porcine dermal collagen implant from which cells, cell debris, DNA, and RNA are removed in a gentle process that is not damaging to the 3D collagen matrix. The resulting acellular collagen matrix is then cross-linked for enhanced durability.
Get your free sample proposal with a single click!